当前位置: 首页 >> 检索结果
1. NURSE-Led Care in Patients Undergoing Catheter Ablation for Atrial Fibrillation: The NURSECAT-AF Randomized Trial.
作者: Alba Cano-Valls.;Maria Antonia Martinez Monblan.;Esther Carro-Fernández.;Mireia Niebla.;Rebeca Domingo.;Sara Hevia-Puyo.;Montserrat Venturas-Nieto.;Roger Borras.;José María Tolosana.;Andreu Porta-Sánchez.;Jean-Baptiste Guichard.;Till F Althoff.;Ivo Roca-Luque.;Lluis Mont.;Eduard Guasch.
来源: Circ Arrhythm Electrophysiol. 2026年19卷3期e014149页
Atrial fibrillation (AF) is associated with reduced quality of life and frequent hospitalizations. Integrated nurse-led care (NLC) has proven beneficial in unselected AF patients, but evidence specific to patients undergoing catheter ablation is limited. We aimed to assess the impact of a structured nurse-led intervention in patients undergoing first-time AF ablation.
2. Risk in Women Emerges at Lower Coronary Plaque Burden Than in Men: PROMISE Trial.
作者: Jan M Brendel.;Thomas Mayrhofer.;Júlia Karády.;Márton Kolossváry.;Nóra M Kerkovits.;Isabel L Langenbach.;Matthias Jung.;Michelle D Kelsey.;Marcel C Langenbach.;Neha Pagidipati.;Svati H Shah.;Michael T Lu.;Maros Ferencik.;Pamela S Douglas.;Borek Foldyna.
来源: Circ Cardiovasc Imaging. 2026年19卷3期e019011页
Quantitative coronary plaque measures differ in prognostic value between women and men. It remains unclear whether cardiovascular risk increases proportionally with plaque extent in both sexes. We aimed to compare cardiovascular risk trajectories across quantitative coronary plaque measures in women and men with stable chest pain.
3. Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.
作者: Mahesh V Madhavan.;John Gregson.;Bjorn Redfors.;Shmuel Chen.;Joseph F Sabik.;Akiko Fujino.;Lak N Kotinkaduwa.;Dimitri Karmpaliotis.;Jeffrey W Moses.;Ori Ben-Yehuda.;Patrick W Serruys.;Stuart Pocock.;A Pieter Kappetein.;Akiko Maehara.;Gregg W Stone.
来源: Circulation. 2026年153卷12期890-901页
Limited data are available regarding the relative rates, etiology, and long-term prognostic implications of spontaneous myocardial infarction (MI) after percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery for left main coronary artery disease (LMCAD).
4. Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.
作者: Julian S Haimovich.;Shinwan Kany.;Yuchiao Chang.;Leila H Borowsky.;David D McManus.;Steven J Atlas.;Daniel E Singer.;Steven A Lubitz.;Patrick T Ellinor.;Shaan Khurshid.
来源: Circulation. 2026年153卷6期367-378页
Stressor-associated atrial fibrillation (AF), defined as newly diagnosed AF in the setting of a reversible physiological stressor, is common. However, risk factors, outcomes, and current management practices remain poorly understood.
5. Balloon- Versus Self-Expanding Transcatheter Valves for Failed Small Surgical Aortic Bioprostheses: 3-Year Results of the LYTEN Trial.
作者: Pedro Cepas-Guillén.;Amr E Abbas.;Vicenç Serra.;Victoria Vilalta.;Luis Nombela-Franco.;Ander Regueiro.;Karim M Al-Azizi.;Ayman Iskander.;Lenard Conradi.;Jessica Forcillo.;Scott Lilly.;Álvaro Calabuig.;Eduard Fernandez-Nofrerias.;Siamak Mohammadi.;Carlos Giuliani.;Emilie Pelletier-Beaumont.;Philippe Pibarot.;Josep Rodés-Cabau.
来源: Circ Cardiovasc Interv. 2026年19卷3期e016255页
Data comparing valve systems in the valve-in-valve transcatheter aortic valve replacement (TAVR) field have been obtained from retrospective studies. This prespecified secondary analysis of the LYTEN randomized trial (Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprostheses) aims to compare the 3-year hemodynamic performance and clinical outcomes between balloon-expandable valves (BEV) SAPIEN 3/ULTRA (Edwards Lifesciences) and self-expanding valves (SEV) Evolut R/PRO/PRO+ (Medtronic) in valve-in-valve TAVR.
6. Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF.
作者: Jawad H Butt.;Alasdair D Henderson.;Pardeep S Jhund.;Brian L Claggett.;Akshay S Desai.;Maria Borentain.;Katja Rohwedder.;Rania Dayoub.;Yoriko De Sanctis.;Carolyn S P Lam.;Michele Senni.;Sanjiv J Shah.;Adriaan A Voors.;Johann Bauersachs.;Cândida Fonseca.;Gerard C M Linssen.;Mark C Petrie.;Morten Schou.;Subodh Verma.;Faiez Zannad.;Bertram Pitt.;Muthiah Vaduganathan.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2026年19卷2期e013201页
The prevalence and prognostic significance of liver biomarkers in heart failure (HF) with mildly reduced or preserved ejection fraction are uncertain, with both potential hemodynamic and metabolic contributions to liver dysfunction in these patients. We evaluated the prevalence and prognostic value of liver biomarkers and assessed the effects of the nonsteroidal mineralocorticoid receptor antagonist finerenone on these biomarkers and clinical outcomes in FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure).
7. Dynamic Change of Coronary Artery Geometry After Bioadaptor Implantation: A Single-blind Randomized Controlled Trial.
作者: Cheng-Hsuan Tsai.;Han-Hsuan Chu.;Ching-Chang Huang.;Chih-Fan Yeh.;Ying-Hsien Chen.;Mao-Shin Lin.;Tsung-Yu Ko.;Chun-Kai Chen.;Yu-Cheng Huang.;Pin-Yi Chiang.;Wen-Jeng Lee.;Hsien-Li Kao.
来源: Circ Cardiovasc Interv. 2026年19卷2期e016191页
The DynamX bioadaptor, a novel coronary implant, is designed to restore vessel function when the thin polymer coating covering the helical strands resorbs 6 months post-percutaneous coronary intervention. We aimed to evaluate vessel conformability 1 year after percutaneous coronary intervention with the bioadaptor, compared with conventional drug-eluting stents (DESs).
8. Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial.
作者: Ayodele Odutayo.;Deepak L Bhatt.;Vikas S Sridhar.;Michael Szarek.;Christopher P Cannon.;Lawrence A Leiter.;Darren K McGuire.;Julia B Lewis.;Renato D Lopes.;Benjamin M Scirica.;Kausik K Ray.;Michael J Davies.;Phillip Banks.;Manon Girard.;Subodh Verma.;Jacob A Udell.;Bertram Pitt.;Ph Gabriel Steg.;David Z I Cherney.
来源: Circ Heart Fail. 2026年19卷3期e013054页
The 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America heart failure (HF) classification incorporates cardiac biomarkers to identify early risk of HF. The HF stages may also guide the prognosis and management of cardiovascular and kidney-related events.
9. Delay From First Symptoms in Patients Presenting With STEMI and Cardiogenic Shock: Insights From the DanGer Shock Trial.
作者: Lisette Okkels Jensen.;Rasmus Paulin Beske.;Hans Eiskjær.;Norman Mangner.;Amin Polzin.;P Christian Schulze.;Carsten Skurk.;Peter Nordbeck.;Peter Clemmensen.;Vasileios Panoulas.;Sebastian Zimmer.;Andreas Schäfer.;Nikos Werner.;Lene Holmvang.;Kristian Wachtell.;Thomas Engstøm.;Nanna Louise Junker Udesen.;Henrik Schmidt.;Anders Junker.;Christian Juhl Terkelsen.;Steffen Christensen.;Axel Linke.;Jacob Eifer Møller.;Christian Hassager.; .
来源: Circ Cardiovasc Interv. 2026年19卷3期e015718页
Microaxial flow pump (mAFP) use in selected patients with ST-segment-elevation myocardial infarction complicated by cardiogenic shock improves survival. The present study aimed to assess the influence of delay from first symptoms to randomization on the benefit of an mAFP in patients with ST-segment-elevation myocardial infarction complicated by cardiogenic shock.
10. Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome.
作者: Sergio Leonardi.;Antonio Landi.;Andrea Zito.;Mattia Branca.;Enrico Frigoli.;Giuseppe Ando'.;Carlo Briguori.;Paolo Calabro.;Andrea Gagnor.;Roberto Garbo.;Dik Heg.;Ugo Limbruno.;Andrea Milzi.;Elmir Omerovic.;Filippo Russo.;Manel Sabaté.;Andrea Santarelli.;Gennaro Sardella.;Paolo Tosi.;Arnoud W J Van't Hof.;Pascal Vranckx.;Marco Valgimigli.
来源: Circulation. 2026年153卷4期230-242页
The universal definition of percutaneous coronary intervention (PCI)-related myocardial infarction (MI) has been substantially updated over the years, including an increase in the biomarker threshold (from 3 to 5 times the upper reference limit) and the introduction of ancillary criteria such as ischemic symptoms and electrocardiographic or angiographic complication. The impact of these changes in patients with acute coronary syndrome (ACS) remains incompletely understood. The objective of this study was to compare prognostic implications of evolving universal definitions of PCI-MI in a large cohort of patients with ACS from the MATRIX trial (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX).
11. Artificial Intelligence-Enabled Echocardiography as a Surrogate for Multimodality Aortic Stenosis Imaging: Post Hoc Analysis of a Clinical Trial.
作者: Evangelos K Oikonomou.;Neil J Craig.;Gregory Holste.;Sumukh Vasisht Shankar.;Audrey C White.;Menaka Mahendran.;David E Newby.;Marc R Dweck.;Rohan Khera.
来源: Circ Cardiovasc Imaging. 2026年19卷2期e018353页
Accurate aortic stenosis (AS) phenotyping requires multimodality imaging which has limited availability. The digital aortic stenosis severity index (DASSi), an artificial intelligence biomarker of AS-related remodeling on single-view 2-dimensional echocardiography, predicts AS progression independent of Doppler measurements. We sought to evaluate the ability of DASSi to define personalized AS progression profiles and to validate its performance as a scalable alternative to multimodality imaging features of functional, structural, and biological AS severity.
12. 4D Digital Heart Model-Guided Left and Right Ventricular Lead Placement for Cardiac Resynchronization Therapy: Results of MAPIT-CRT Trial.
作者: Derek S Chew.;Bert Vandenberk.;Derek V Exner.;Dina Labib.;Jacqueline Flewitt.;Yoko Mikami.;Sandra Rivest.;Denise Chan.;Jaimie Manlucu.;Peter Leong-Sit.;Claus Rinne.;David H Birnie.;Pablo B Nery.;Glen Sumner.;Félix Ayala-Paredes.;François Philippon.;Raymond Yee.;James A White.
来源: Circ Arrhythm Electrophysiol. 2026年19卷1期e014132页
Suboptimal left ventricular (LV) and right ventricular lead positioning has been associated with a lesser response to cardiac resynchronization therapy. The MAPIT-CRT (MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy) randomized controlled trial evaluated a novel, cardiac magnetic resonance-generated 4-dimensional phenomics cardiac magnetic resonance imaging (4DPcmr) lead placement strategy.
13. Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra.
作者: Benjamin W Van Tassell.;Michele Golino.;Justin M Canada.;Roshanak Markley.;Hayley Billingsley.;Marco Giuseppe Del Buono.;Azita Talasaz.;Georgia Thomas.;Juan Guido Chiabrando.;George Wohlford.;Virginia Dickson.;Dinesh Kadariya.;Juan Ignacio Damonte.;Ai-Chen Jane Ho.;Yub Raj Sedhai.;Emily Kontos.;Alessandra Vecchiè.;Joshua D West.;Giuliana Corna.;Horacio Medina de Chazal.;Sebastian Pinel.;Edoardo Bressi.;Andrew Barron.;Megan Dell.;James Mbualungu.;Francesco Moroni.;Jeremy Turlington.;Emily Federmann.;Cory R Trankle.;Salvatore Carbone.;Ross Arena.;Antonio Abbate.
来源: Circ Heart Fail. 2026年19卷3期e013546页
Decompensated heart failure with reduced ejection fraction (HFrEF) is associated with systemic inflammation that predicts unfavorable outcomes. We aimed to determine whether anakinra, an IL-1 (interleukin-1) blocker, favors inflammation resolution (CRP [C-reactive protein]) and improves peak oxygen consumption (VO2) in patients with recently decompensated HFrEF.
14. Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Results of the AIM-POWER Trial.
作者: Adam D DeVore.;Maulik Majmudar.;Leigh Etters.;Jiecheng Xie.;Chen Hao.;Phillip H Lam.;Adrian F Hernandez.;Gregg C Fonarow.;Akshay S Desai.
来源: Circ Heart Fail. 2026年19卷2期e013231页
Less than 1 in 3 patients in the United States with heart failure (HF) with reduced ejection fraction are receiving guideline-recommended medical therapy. Remote titration programs outside of structured episodes of care may address this issue and improve the implementation of guideline-recommended care.
15. Physical Exercise or Cognitive Behavioral Therapy for Takotsubo Cardiomyopathy: A Randomized Controlled Trial.
作者: David T Gamble.;James Ross.;Hilal Khan.;Lesley Cheyne.;Amelia Rudd.;Janaki Srivanasan.;Graham Horgan.;Duncan Hogg.;Phyo K Myint.;David E Newby.;Christopher Williams.;Stuart R Gray.;Dana Dawson.
来源: Circ Heart Fail. 2026年19卷3期e013229页
Takotsubo cardiomyopathy is an acute cardiac emergency presenting with severe left ventricular dysfunction. Physical exercise training or cognitive behavioral therapy may enhance myocardial recovery after takotsubo cardiomyopathy.
16. Calcium Modification After Orbital Atherectomy and Balloon Angioplasty in Severely Calcified Lesions: The ECLIPSE OCT Substudy.
作者: Akiko Maehara.;Ajay J Kirtane.;Philippe Généreux.;Mitsuaki Matsumura.;Bruce E Lewis.;Richard A Shlofmitz.;Suhail Dohad.;Jithendra Choudary.;Thom Dahle.;Andres M Pineda.;Kendrick A Shunk.;Alexandra Popma.;Bjorn Redfors.;Ziad A Ali.;Mitchell W Krucoff.;Ehrin J Armstrong.;David E Kandzari.;Kanitha Phalakornkule.;Carlye Kraemer.;Krista M Stiefel.;Denise E Jones.;Jana R Buccola.;Jeffrey W Chambers.;Gregg W Stone.
来源: Circ Cardiovasc Interv. 2026年19卷1期e015588页
The treatment of calcified coronary lesions requires optimal lesion preparation to achieve a larger minimal stent area (MSA), the strongest predictor of long-term outcomes. The comparative mechanisms of action of calcium-modifying therapies have not been well defined.
17. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.
作者: Sotirios Tsimikas.;Michael Szarek.;Christa M Cobbaert.;Fred Romijn.;J Wouter Jukema.;Deepak L Bhatt.;Vera A Bittner.;Rafael Diaz.;Sergio Fazio.;Genevieve Garon.;Chong Yuan.;Xiao-Min Gong.;Shaun G Goodman.;Harvey D White.;Joseph L Witztum.;P Gabriel Steg.;Gregory G Schwartz.; .
来源: Circulation. 2025年152卷24期1666-1678页
Oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) reflect pro-inflammatory properties of Lp(a) (lipoprotein(a)). The effect of OxPL-apoB on major adverse cardiovascular events (MACE) in patients with acute coronary syndrome in recent the era is not known.
18. Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.
作者: Marcely Gimenes Bonatto.;Mônica Samuel Avila.;Sílvia Moreira Ayub Ferreira.;Luka David Lechinewski.;Rafael de Almeida Torres.;Amanda de Nadai Costa.;Nadya Rocumback Alves da Costa.;Andressa de Oliveira Coiradas.;Talita Beithum Ribeiro Mialski.;Julyana Maiolino.;Tammy Tiemy Ota.;Laís Contin.;Larissa Arlete Mosko.;Marcio Sommer Bittencourt.;Sanderson Cauduro.;Lídia Ana Zytynski Moura.;Edimar Alcides Bocchi.
来源: Circulation. 2025年152卷25期1742-1755页
The clinical effects of sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, on anthracycline-induced cardiotoxicity remain unknown. Experimental evidence suggests cardioprotective properties. This study evaluated the efficacy of sacubitril-valsartan in reducing cardiotoxicity in patients with increased cardiac troponin I concentrations during anthracycline chemotherapy.
19. Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.
作者: Marianna Fontana.;Pablo García-Pavía.;Martha Grogan.;Sanjiv J Shah.;Mads D M Engelmann.;G Kees Hovingh.;Arnt V Kristen.;Michelle Z Lim-Watson.;Brian Malling.;Soumitra Kar.;Manjunatha Revanna.;Nitasha Sarswat.;Kenichi Tsujita.;Kevin M Alexander.;Mathew S Maurer.
来源: Circulation. 2026年153卷4期214-225页
Transthyretin amyloidosis with cardiomyopathy is a progressive disease caused by the deposition of transthyretin (TTR) as amyloid in the myocardium. Current therapies may slow disease progression but do not clear existing deposits. Coramitug is a humanized monoclonal antibody that targets misfolded transthyretin, designed to promote clearance of transthyretin amyloid through antibody-mediated phagocytosis.
20. Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial.
作者: William F Fearon.;Kosei Terada.;Kuniaki Takahashi.;Anette Skoda.;Helen I Luikart.;Cynthia A Lamendola.;Frederik M Zimmermann.;Takehiro Hashikata.;Kan Saito.;Akihiro Yoshida.;Brandon Varr.;Joshua W Knowles.;Christopher Woo.;Yasuhiro Honda.;Jeffrey Teuteberg.;Kiran K Khush.
来源: Circulation. 2026年153卷1期7-17页
Cardiac allograft vasculopathy is an important cause of mortality after heart transplantation (HT). Dyslipidemia is a major contributor to the development of cardiac allograft vasculopathy. The safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and to prevent cardiac allograft vasculopathy early after HT are not well established.
|